Investor FAQ

Our ADS shares began trading on February 5, 2021.

The initial public offering price was US $10.

Our ADS shares are listed on the NASDAQ Capital Market under the ticker symbol EVAX.

An American depositary share (ADS) is the U.S. dollar-denominated equity share of a foreign-based company available for purchase on an American stock exchange.

With effective date 22 January 2024, the Company has changed its ratio of its American Depositary Shares (“ADSs”). The ratio has changed from one (1) ADS representing one (1) ordinary share to a new ADS Ratio of one (1) ADS representing ten (10) ordinary shares.
 

In connection with transfer of shares and issuance of ADSs shareholders and warrantholders should therefore be aware that if ordinary shares are to be converted into ADSs, a number of ordinary shares divisible with 10 must be converted.
 

Shareholders and warrantholders who, after conversion of shares into ADSs hold 9 ordinary shares or a smaller number of ordinary shares and therefore are not able to convert such remaining ordinary shares into ADSs are encouraged to contact the Company to discuss the possibilities of a sale of such remaining ordinary shares.

The Bank of New York Mellon, Inc.(“BNY Mellon’) acts as Depositary for the Depositary Receipt ("DR") program of Evaxion Biotech A/S, pursuant to a deposit agreement among BNY Mellon and Evaxion Biotech A/S.

Evaxion has never declared or paid any cash dividends and does not anticipate doing so in the foreseeable future. The company intends to retain all attainable funds to fund the development of its business.

Duane Morris LLP, New York, New York is Evaxion’s US legal counsel. Mazanti-Andersen, Copenhagen, Denmark is Evaxion’s Danish legal counsel.